Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 27;293(34):13191–13203. doi: 10.1074/jbc.RA118.002649

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Brenke et al.

Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

Figure 6. — Topical application of the inhibitor C25-140 reduces in vivo outcome of imiquimod-induced psoriasis. A, preclinical mouse model for IMQ-induced psoriasis. Mice (n = 8/group) were topically treated with IMQ to the back and ear once a day. C25-140 was topically applied twice daily. Mice were scored throughout the study, and samples were collected at day 6 for cytokine measurement. B–E, mice were scored for cumulative score (B), thickness score (C), scaling (D), and erythema (E). All symptoms were improved by C25-140 treatment; error bars, S.D.; two-way ANOVA test (Sidak's multiple-comparison test). F, IL-17 cytokine levels were evaluated by ELISA and show a significant decrease after treatment; unpaired t test (two-tailed); error bars, S.D.; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.